Minimally Invasive Lumbar Interbody Fusion With an Expandable Meshed Allograft Containment Device: Analysis of Subsidence With 12-Month Minimum Follow-Up

JOHN PAUL G. KOLCUN, MD,1 GEORGE M. GHOBRIAL, MD,1 KENNETH M. CRANDALL, MD,1 KEN HSUAN-KAN CHANG, MD,2 GIACOMO PACCHIAROTTI, MS,3 MICHAEL Y. WANG, MD1

1Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, Florida, 2Department of Neurological Surgery, National Yang-Ming University School of Medicine, Taipei, Taiwan, 3Institute of Neurosurgery, University of Rome “La Sapienza,” Rome, Italy

ABSTRACT

Background: We have previously reported the use of a minimally invasive allograft-filled expandable meshed-bag containment system in the lumbar spine. Subsidence has not been reported with this device. In this retrospective case series, we describe subsidence after lumbar interbody fusion using this device, with 12-month minimum radiographic follow-up.

Methods: Consecutive adult patients that underwent 1- or 2-level interbody fusion with at least 1 year of follow-up were included in this study. Preoperative, postoperative, and final follow-up lumbar radiographs were analyzed to measure disc height at the anterior and posterior margins of the disc space, as well as the neuroforaminal height.

Results: Forty-one patients were identified, with a mean age of 63.4 years (± 11.8). A total of 61 levels were treated, with successful fusion observed in 54 levels (88.5%). The mean radiographic follow-up was 24.3 months (± 11.2). The mean disc height pre- and postoperatively was 6.9 mm (± 3.2) and 10.1 mm (± 2.9, \( P < .001 \)), respectively. The mean disc height at final follow-up was 8.3 mm (± 2.4). Average disc height subsidence was 1.8 mm (± 1.7, \( P < .001 \)). Overall, average disc height increased by a net 1.3 mm (± 2.5, \( P < .001 \)). The mean neuroforaminal height pre- and postoperatively was 18.0 mm (± 3.3) and 20.7 mm (± 3.6, \( P < .001 \)), respectively. The mean neuroforaminal height at final follow-up was 19.2 mm (± 3.4). Average neuroforaminal height subsidence was 1.3 mm (± 3.4, \( P = .012 \)). Overall, average neuroforaminal height increased by a net 1.7 mm (± 2.8, \( P = .004 \)). No significant difference in subsidence was observed between 1- and 2-level surgeries.

Conclusion: An expandable allograft containment system is a feasible alternative for lumbar interbody fusion. Due to its biologic and mechanical nature, the surgeon using such constructs should account for an anticipated average of 18% loss of interbody height due to subsidence during the bony remodeling/fusion process.

New Technology

Keywords: lumbar interbody fusion, transforaminal lumbar interbody fusion, minimally invasive surgery, interbody device, subsidence

INTRODUCTION

As populations age, the annual rate of lumbar fusion procedures performed in developed nations is steadily increasing. Open lumbar interbody fusion procedures can carry a higher morbidity in elderly patients due to increased comorbidities and impaired cardiopulmonary reserves. These patients also tend to have a longer postoperative recovery period. The current drive to decrease surgical invasiveness while achieving the same operative outcomes benefits fragile patient populations, such as the elderly. Minimally invasive surgery (MIS) embodies the attempt to decrease surgical morbidity, postoperative pain, and the postoperative hospital recovery period. Compared to the traditional open approach, MIS transforaminal lumbar interbody fusion (TLIF) has been associated with reduced blood loss and tissue destruction, earlier mobilization, and shorter hospital stays. While the traditional open TLIF approach offers a larger working channel for endplate preparation, fusion rates between open and MIS TLIF are generally comparable. Subsidence greater than 3 mm is generally considered significant, and acceptable rates of subsidence have been reported with both open and MIS techniques.

The OptiMesh device (Spineology, Saint Paul, Minnesota) is a small, expandable polyethylene meshed sac, originally designed to contain allograft within a vertebral body defect. However, the
OptiMesh can also be placed within the interbody space with reduced approach-related tissue destruction, while still achieving sufficient endplate preparation. With this method, fusion rates comparable to other interbody devices may be attainable. Over time, however, excessive graft subsidence could potentially restrict the neuroforamen, leading to a recurrence of symptoms.

The authors report the use of an OptiMesh expandable meshed allograft containment system for 1- or 2-level lumbar degenerative indications, with a minimum 12-month radiographic follow-up.

MATERIALS AND METHODS

Data Collection

Consecutive records in a single-surgeon database (M.Y.W.) were reviewed for patients greater than 18 years old who underwent interbody fusion with the OptiMesh device at a single institution from August 2009 to October 2015. It should be noted that this application of the cage is designated as “off-label” by the US Food and Drug Administration. Patients included in this study were treated for 1- or 2-level lumbar disease with a minimum of 12 months of follow-up. Demographic, clinical, and operative information was collected for each patient, including age, sex, tobacco use, indication for surgery, operative level, estimated blood loss, fusion rate, postoperative hospital stay, complications, and length of follow-up.

Surgical Technique

The technique used to place this device in the lumbar interbody space has been reported previously. Height restoration is achieved with increasing allograft placement in the graft containment system, which grows to fill and expand the interbody space. Recombinant human bone morphogenetic protein-2 (rhBMP-2, Infuse, Medtronic, Minneapolis, Minnesota) at a dose of up to 1.05 mg/level is utilized prior to mesh graft placement (within the interbody space but outside the cage).

Radiographic Measurements

Anteroposterior (AP), lateral, and dynamic flexion/extension x-ray images for each patient were reviewed and measured. The lateral lumbar x-ray was reviewed for disc height, neuroforaminal height, anterolisthesis, lumbar lordosis, and interbody angle. Lumbar Cobb angle was measured from AP lumbar views. Computed tomography (CT) images and dynamic x-rays were reviewed to assess fusion (Figure 2).

Subsidence was defined as a loss of average disc height and/or neuroforaminal height between postoperative and final images. Successful postoperative fusion was defined as: (1) continuous bridging bone observed on CT scan or, if CT was unavailable or inconclusive, (2) < 3° of motion and < 3 mm of translation observed on dynamic lumbar lateral x-ray (flexion/extension), with no evidence of screw dislodgment, migration, or screw-rod breakage (Figure 3).

Statistical Analysis

Continuous variables were analyzed with 2-tailed paired Student t tests (pre- versus postoperative) and 2-tailed independent Welch t-tests (1 versus 2 levels). Categorical variables were analyzed with a Pearson χ² test. A P value of < .05 was considered statistically significant. Continuous variables are reported as mean (± SD). Categorical variables are reported as n (%). Statistical calculations were performed in Microsoft Excel 2011 (Microsoft, Redmond, Washington).

RESULTS

Population Characteristics

Forty-one patients were identified, with a mean age of 63.4 years (± 11.8). A majority of patients...
were female (29, 70.7%). A total of 61 spinal levels were treated, with a majority of procedures performed at the L4-5 level (29, 70.7%). Roughly one-quarter of patients reported tobacco use (11, 26.8%). The most common indication for surgery was spondylolisthesis (22, 53.7%). The average blood loss was estimated at 203.9 mL (± 186.5). Fusion was observed in 54 levels (88.5%) by the 12-month interim. Patients spent an average 4.3 days (± 2.3) in the hospital postoperatively. One complication was observed (2.4%): a fractured rod, which occurred in a patient with pseudoarthrosis. The mean radiographic follow-up was 24.3 months (± 11.2) (Table 1).

Radiographic Outcomes

Postoperatively, disc height increased by 3.1 mm (± 1.9, 66.5%, \( P < .001 \)) and neuroforaminal height increased by 3.0 mm (± 3.3, 19.1%, \( P < .001 \)). At final follow-up, the disc height had decreased by 1.8 mm (± 1.7, 15.5%, \( P < .001 \)) and neuroforaminal height had decreased by 1.3 mm (± 3.4, 4.3%, \( P = .012 \)) from postoperative levels. Interbody angle decreased by 0.8° (± 2.9, 5.2%, \( P = .033 \)) between postoperative and final imaging. Neuroforaminal height change was significantly less than that of the average disc height (4.3% versus 15.5%, \( P < .001 \)). From baseline to final radiographic follow-up, disc height increased by a net 1.3 mm (± 2.5, 42.8%, \( P < .001 \)) and neuroforaminal height increased by a net 1.7 mm (± 2.8, 11.2%, \( P = .004 \)) (Figure 4).

Similar results were seen in a net reduction of anterolisthesis by 1.3 mm (± 2.6, 29.9%, \( P = .004 \)) and lumbar Cobb angle by 1.1° (± 4.3, 20.5%, \( P = .078 \)), and a net increase in lumbar lordosis by 0.3° (± 11.9, 14.4%, \( P = .100 \)). While less robust, these effects were significant (Table 2). Radiographic parameters in patients undergoing 1- or 2-level surgery were compared. Differences in demographics were assessed to justify comparing these groups. A greater number of 2-level patients reported tobacco use (\( P = .010 \)). Total follow-up

---

**Table 1.** Baseline population characteristics, indications, and outcomes. Continuous variables are represented as mean ± SD, and categorical variables as n (%).

| Parameter                  | Value          |
|----------------------------|----------------|
| Demographics               |                |
| No. of patients            | 41             |
| Age (years)                | 63.4 ± 11.8    |
| Sex ratio (M:F)            | 12 (29.3):29 (70.7) |
| Tobacco use                | 11 (26.8)      |
| Operative level            |                |
| L2-3                       | 2 (4.9)        |
| L3-4                       | 15 (36.6)      |
| L4-5                       | 29 (70.7)      |
| L5-S1                      | 15 (36.6)      |
| Outcomes                   |                |
| Fusion (levels)            | 54 (88.5)      |
| EBL (mL)                   | 203.9 ± 186.5  |
| LOS (days)                 | 4.3 ± 2.3      |
| Complications              | 1 (2.4)        |
| Follow-up (months)         |                |
| Clinical                   | 28.4 ± 13.5    |
| Radiographic               | 24.3 ± 11.2    |

Abbreviations: EBL, estimated blood loss; LOS, length of hospital stay.

---

**Figure 2.** Illustration of x-ray measurements, showing lumbar Cobb angle (A), lumbar lordosis (B1), neuroforamen height (B2), posterior disc height (B3), anterior disc height (B4), anterolisthesis (B5), and postoperative interbody angle (C).

**Figure 3.** Representative lateral lumbar x-ray sequence in a single patient, showing preoperative (A), postoperative (B), and long-term follow-up (C) images. Note the changes in disc and neuroforaminal height: a marked increase from A to B, and slight decrease from B to C.

**Figure 4.** Total population radiographic findings. Disc space and neuroforamen height (both in mm) shown at baseline, postoperative, and final follow-up.
DISCUSSION

In this retrospective study using an expandable meshed allograft-containment interbody device, we find that rates of fusion and graft subsidence at a minimum 12 months postoperatively are not inferior to those reported with conventional interbody devices.

No prior reports describe subsidence rates for the OptiMesh system in patients with 1- and 2-level lumbar degenerative disc disease. This information is of particular importance while measuring the disc space height preoperatively to determine graft height selection, as oversizing of interbody grafts has been implicated as the single most important technique-related risk for subsidence.

MIS techniques are designed to reduce approach-related soft tissue trauma and operative duration with the goal of delivering equivalent outcomes with a shorter recovery time. However, the adoption and promotion of new surgical technology must be predicated on demonstrated, long-term efficacy. Cadaveric studies have demonstrated the relationship between disc height, neuroforamen height, and nerve compression, as well as the biomechanical capability of the OptiMesh expandable device to manipulate this anatomy effectively. Numerous reports have shown the durability of expandable technologies in providing symptomatic relief via indirect decompression. We have previously reported our use of the OptiMesh device in 25 patients with adult degenerative scoliosis after 1 year of follow-up, demonstrating no recurrent radiculopathic symptoms along the concavity. In this study, significant improvements were achieved.

| Table 2. Total sample radiographic measurements at baseline, postoperatively, and at most recent follow-up. All values are represented as mean ± SD. All lengths are given in millimeters, and all angles shown in degrees. Comparisons between time points are shown with results of 2-tailed paired Student t tests. |
|---|---|---|---|---|
| Disc Height | Anterior | Posterior | Average |
| Baseline | 9.2 ± 4.4 | 5.1 ± 2.2 | 6.9 ± 3.2 |
| Postoperative | 12.8 ± 3.1 | 8.2 ± 2.3 | 10.1 ± 2.9 |
| Change from baseline | 3.3 ± 2.7 | 2.9 ± 2.2 | 3.1 ± 1.9 |
| Change from baseline, % | 56.9 | 87.2 | 66.5 |
| P value | <.001 | <.001 | <.001 |
| Final | 10.8 ± 2.5 | 6.6 ± 2.0 | 8.3 ± 2.4 |
| Change from postop | −2.0 ± 2.0 | −1.5 ± 1.8 | −1.8 ± 1.7 |
| Change from postop, % | −15.0 | −17.1 | −15.5 |
| P value | <.001 | <.001 | <.001 |
| Net changes | 1.3 ± 3.4 | 1.4 ± 2.6 | 1.3 ± 2.5 |
| Change from baseline | 34.6 | 57.9 | 42.8 |
| Change from baseline, % | .062 | .002 | <.001 |
| P value | .004 | .004 | .010 |

| Table 3. Subgroup population characteristics, indications, and outcomes. Continuous variables are represented as mean ± SD, and categorical variables as n (%). Comparisons shown as results of 2-tailed Welch t test (continuous variables) and Pearson χ² test (categorical variables). P-values achieving statistical significance are shown in bold. |
|---|---|---|---|
| Demographics | 1 Level | 2 Levels | P Value |
| No. of patients | 21 | 20 | .539 |
| Age (years) | 62.2 ± 12.0 | 64.6 ± 11.8 | .558 |
| Sex ratio (M:F) | 7 (33.3:14 (66.7) | 5 (25.0):15 (75.0) | .010 |
| Tobacco use | 2 (9.5) | 9 (45.0) | .000 |
| Operative level | | | |
| L2-3 | 1 (4.8) | 1 (2.5) | .637 |
| L3-4 | 2 (9.5) | 13 (32.5) | .048 |
| L4-5 | 10 (47.6) | 19 (47.5) | .993 |
| L5-S1 | 8 (38.1) | 7 (17.5) | .076 |
| Outcomes | | | |
| Fusion (levels) | 18 (85.7) | 34 (85.0) | .940 |
| EBL (mL) | 205.3 ± 236.2 | 202.6 ± 125.2 | .966 |
| LOS (days) | 4.1 ± 2.7 | 4.7 ± 1.6 | .397 |
| Complications | 1 (2.4) | 0 (0) | .323 |
| Follow-up (months) | Clinical | 26.9 ± 16.4 | 30.0 ± 9.7 | .473 |
| Radiographic | 20.2 ± 7.3 | 28.4 ± 12.9 | .019 |

Abbreviations: EBL, estimated blood loss; LOS, length of hospital stay.
in the Cobb angle (20.2° reduction), lumbar lordosis (14.8° increase), and global sagittal alignment (3.1-cm reduction). Improvements were also seen in various clinical parameters, including the numeric pain scale extremity score (3.3-point reduction), numeric pain scale axial back score (4.2-point reduction), and Oswestry disability index (20.8-point reduction). 8

A number of methods for evaluating postoperative fusion and subsidence have been described previously. Early methods for assessing segmental fusion relied on standing radiographs, which could be used to observe bridging bone through the fusion mass or segmental motion during flexion or extension. 17,18 Later studies determined that CT imaging is a more accurate and reliable measure of the presence and quality of fusion. 19,20 Consequently, we utilized CT images whenever possible to assess fusion in our patients. Observation of fusion bridging through the OptiMesh graft is a particular challenge due to the homogenous hyperdense radiographic appearance of the graft in the inter-

Table 4. Subgroup radiographic measurements at baseline, postoperatively, and at most recent follow-up. All values are represented as mean ± SD. All lengths are given in millimeters, and all angles shown in degrees. Comparisons of percentage of change at each point are shown with results of 2-tailed Welch t tests.

| Disc Height | Foraminal Height | Anterolisthesis | Lumbar Lordosis | Lumbar Cobb Angle | Interbody Angle |
|-------------|------------------|-----------------|-----------------|------------------|-----------------|
| Anterior    | Posterior        | Average         |                 |                  |                 |
| Baseline    |                  |                 |                 |                  |                 |
| 1 level     | 9.4 ± 4.1        | 5.0 ± 1.7       | 6.8 ± 2.4       | 17.4 ± 3.1       | 3.0 ± 4.1       | 41.6 ± 14.5     |
| 2 levels    | 9.1 ± 4.6        | 5.2 ± 2.5       | 7.0 ± 3.5       | 18.4 ± 3.4       | 4.0 ± 3.6       | 38.2 ± 13.7     |
| Postop      |                  |                 |                 |                  |                 |                 |
| 1 level     | 13.4 ± 3.0       | 7.9 ± 2.0       | 10.3 ± 2.3      | 20.6 ± 3.3       | 1.5 ± 2.5       | 47.0 ± 10.9     |
| Change from baseline | 3.8 ± 2.4       | 3.2 ± 1.1       | 3.5 ± 1.7       | 3.5 ± 1.5       | 1.1 ± 2.7       | 5.4 ± 7.8       |
| Change from baseline, % | 65.9 ± 21.2     | 95.3 ± 70.3     | 20.5 ± 27.4     | 66.3 ± 20.7     | 21.2 ± 10.7     | 7.9 ± 10.2      |
| 2 levels    | 12.4 ± 3.1       | 8.4 ± 2.5       | 9.9 ± 3.2       | 20.7 ± 3.8       | 2.5 ± 3.2       | 38.7 ± 13.2     |
| Change from baseline | 3.1 ± 2.9       | 2.7 ± 2.4       | 2.9 ± 2.0       | 2.8 ± 3.9       | 1.4 ± 2.6       | 0.5 ± 7.0       |
| Change from baseline, % | 51.9 ± 27.2     | 82.4 ± 64.4     | 18.4 ± 30.9     | 4.5 ± 11.3      | 26.1 ± 14.4     | 9.8 ± 19.8      |
| P value     | .491             | .722            | .799            | .682             | .834            | .250            | .989            |
| Final       |                  |                 |                 |                  |                 |                 |
| 1 level     | 12.0 ± 2.6       | 6.4 ± 1.6       | 8.8 ± 2.0       | 18.9 ± 3.1       | ...             | 45.3 ± 14.1     |
| Change from postop | 2.0 ± 2.6       | −1.8 ± 2.0      | −1.9 ± 2.2      | −2.4 ± 5.0       | ...             | −3.8 ± 9.1      |
| Change from postop, % | −15.8 ± 26.2    | −20.7 ± 17.9    | −17.0 ± 10.4    | −10.4 ± 16.8    | ...             | −10.6 ± 16.6    |
| 2 levels    | 10.1 ± 2.2       | 6.8 ± 2.3       | 8.1 ± 2.6       | 19.4 ± 3.6       | ...             | 40.1 ± 13.6     |
| Change from postop | 2.3 ± 2.2       | −1.5 ± 1.9      | −1.9 ± 1.8      | −1.3 ± 4.1       | ...             | 1.4 ± 5.2       |
| Change from postop, % | −16.7 ± 26.2    | −17.3 ± 16.3    | −16.3 ± 3.5     | ...              | 5.3 ± 26.1      | .050 ± .447     |
| P value     | .895             | .628            | .791            | .256             | ...             | .082            |
| Net changes |                  |                 |                 |                  |                 |                 |
| 1 level     | 2.3 ± 3.4        | 1.7 ± 2.5       | 1.6 ± 3.0       | 2.0 ± 1.6        | 1.1 ± 2.7       | 3.8 ± 5.6       |
| Change from baseline | 52.9 ± 26.2     | 70.0 ± 49.1     | 12.0 ± 27.4     | 27.4 ± 30.5      | ...             | −30.1 ± 21.9    |
| 2 levels    | 0.8 ± 3.3        | 1.2 ± 2.6       | 1.0 ± 2.4       | 1.5 ± 3.2        | 1.4 ± 2.6       | 1.9 ± 7.4       |
| Change from baseline | 23.6 ± 26.2     | 49.2 ± 35.5     | 10.5 ± 30.9     | 30.9 ± 8.2       | ...             | −5.4 ± 0.7      |
| P value     | .270             | .623            | .661            | .707             | .834            | .327            | .239            |

Figure 5. Subgroup radiographic findings. Average disc height (mm) shown at baseline, postoperative, and final follow-up. There were no significant differences in disc height or subsidence between 1- and 2-level patients.

Figure 6. Subgroup radiographic findings. Neuroforaminal height (mm) shown at baseline, postoperative, and final follow-up. There were no significant differences in neuroforaminal height or subsidence between 1- and 2-level patients.
body space, likely the result of impacting morcelized allograft into the fixed-volume mesh bag. Therefore, traditional methods of observing bridging fusion through the structural graft via the cancellous portion were not always feasible in our patient sample.\textsuperscript{17} Instead, flexion-extension imaging—a reliable method for determining the absence of fusion—could be used to assess fusion in this subset of patients, as previously described.\textsuperscript{10}

Previous studies have reported subsidence rates with other expandable implants. Loss of interbody height with expandable polyaryl-ether-ether-ketone (PEEK) spacers has been reported from 0.6 to 1.1 mm in patients with follow-up comparable to the present study, and higher (2 to 4 mm) with longer follow-up.\textsuperscript{9,11,21} Isaacs et al compared outcomes utilizing PEEK spacers placed either by MIS lateral interbody fusion or by MIS TLIF.\textsuperscript{22} They found greater subsidence with MIS TLIF as compared to the lateral approach, which was thought to be due to the larger graft footprint and the ability to contact the denser apophyseal ring. However, both MIS and lateral lumbar interbody fusion subsidence rates were comparable with findings in previous literature regarding PEEK spacers, as well as the present study of the OptiMesh device (1.3 mm with MIS TLIF versus 0.8 mm with lateral lumbar interbody fusion). Only one prior study reported neuroforaminal subsidence, with an average loss of 1.1 mm height at 12 months.\textsuperscript{11} This study failed to achieve significant postoperative improvement in the neuroforaminal height over the full course of follow-up.

Our results suggest that the OptiMesh system offers an acceptable subsidence rate at 1 to 2 years postoperatively, at levels similar to previous reports. However, variation in the use and dosage of rhBMP-2 may influence subsidence, precluding a strong, direct comparison between studies.\textsuperscript{12,23} The use of rhBMP-2 has been associated with both accelerated postoperative fusion\textsuperscript{24} and an increased rate of subsidence,\textsuperscript{25,26} among other complications. To date, the optimal dosage and indications for rhBMP-2 have yet to be rigorously defined.\textsuperscript{23}

The use of the OptiMesh graft allows safe access to the disc space with minimal tissue destruction, as demonstrated by the absence of durotomy, symptomatic nerve injuries, and wound-healing complications, all of which have been reported with open TLIF and posterior lumbar interbody fusion procedures.\textsuperscript{27} Further, there was no significant difference in subsidence rates between patients treated at either 1 level or 2 consecutive levels. These results are promising for future study of maintenance of clinical outcomes with the OptiMesh expandable device to further evaluate the durability of this interbody device.

Limitations of this study include the retrospective design, lack of clinical outcomes measures, and follow-up limited to 1 year. Prospective study of the interbody system with an emphasis on radiographic and clinical endpoints at regular postoperative intervals would be the ideal method to determine precisely the incidence, rate, and clinical relevance of subsidence with the OptiMesh expandable device.

CONCLUSION

The use of the OptiMesh graft containment device for 1- or 2-level lumbar interbody fusion is feasible, with a high fusion rate at 12 months. While a low incidence and degree of subsidence was observed, further study in a prospective fashion would better characterize these endpoints and their clinical significance.

REFERENCES

1. Martin BI, Turner JA, Mirza SK, Lee MJ, Comstock BA, Deyo RA. Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997–2006. *Spine (Phila Pa 1976)*. 2009;34(19):2077–2084.

2. Wang MY, Widi G, Levi AD. The safety profile of lumbar spinal surgery in elderly patients 85 years and older. *Neurosurg Focus*. 2015;39(4):E3.

3. McAfee PC, Garfin SR, Rodgers WB, Allen RT, Phillips F, Kim C. An attempt at clinically defining and assessing minimally invasive surgery compared with traditional “open” spinal surgery. *SAS J*. 2011;5(4):125–130.

4. Kulkarni AG, Bohra H, Dhruv A, Sarraf A, Bassi A, Patil VM. Minimal invasive transforminal lumbar interbody fusion versus open transforminal lumbar interbody fusion. *Indian J Orthop*. 2016;50(5):464–472.

5. Wu RH, Fraser JF, Hartl R. Minimal access versus open transforminal lumbar interbody fusion: meta-analysis of fusion rates. *Spine (Phila Pa 1976)*. 2010;35(26):2273–2281.

6. Schiffman M, Brau SA, Henderson R, Gimmestad G. Bilateral implantation of low-profile interbody fusion cages: subsidence, lordosis, and fusion analysis. *Spine J*. 2003;3(5):377–387.

7. Lim JK, Kim SM. Radiographic results of minimally invasive (MIS) lumbar interbody fusion (LIF) compared with conventional lumbar interbody fusion. *Korea J Spine*. 2013;10(2):65–71.

8. Wang MY. Improvement of sagittal balance and lumbar lordosis following less invasive adult spinal deformity surgery with expandable cages and percutaneous instrumentation. *J Neurosurg Spine*. 2013;18(1):4–12.
9. Alimi M, Shin B, Macielak M, et al. Expandable polyarylether-ether-ketone spacers for interbody distraction in the lumbar spine. Global Spine J. 2015;5(3):169–178.

10. Isaacs RE, Sembrano JN, Tohmeh AG. Two-year comparative outcomes of MIS lateral and MIS transforaminal interbody fusion in the treatment of degenerative spondylolisthesis: part II: radiographic findings. Spine (Phila Pa 1976). 2016;41(Suppl 8):S133–S144.

11. Kim CW, Doerr TM, Luna IY, et al. Minimally invasive transforaminal lumbar interbody fusion using expandable technology: a clinical and radiographic analysis of 50 patients. World Neurosurg. 2016;90:228–235.

12. Le TV, Baaj AA, Dakwar E, et al. Subsidence of polyetheretherketone intervertebral cages in minimally invasive lateral retroperitoneal transpsoas lumbar interbody fusion. Spine (Phila Pa 1976). 2012;37(14):1268–1273.

13. Hasegawa T, An HS, Haughton VM, Nowicki BH. Lumbar foraminal stenosis: critical heights of the intervertebral discs and foramina. A cryomicrotome study in cadaver. J Bone Joint Surg. 1995;77(1):32–38.

14. Zheng X, Chaudhari R, Wu C, Mehdob AA, Erkan S, Transfeldt EE. Biomechanical evaluation of an expandable meshed bag augmented with pedicle or facet screws for percutaneous lumbar interbody fusion. Spine J. 2010;10(11):987–993.

15. Behrbalk E, Uri O, Parks RM, Musson R, Soh RC, Boszczyk BM. Fusion and subsidence rate of stand alone anterior lumbar interbody fusion using PEEK cage with recombinant human bone morphogenetic protein-2. Eur Spine J. 2013;22(12):2869–2875.

16. Cannestra AF, Peterson MD, Parker SR, Roush TF, Bundy JV, Turner AW. MIS expandable interbody spacers: a literature review and biomechanical comparison of an expandable MIS TLIF with conventional TLIF and ALIF. Spine (Phila Pa 1976). 2016;41(Suppl 8):S44–S49.

17. Lenke LG, Bridwell KH, Bullis D, Betz RR, Baldus C, Schoenecker PL. Results of in situ fusion for isthmic spondylolisthesis. J Spinal Disord. 1992;5(4):433–442.

18. Frobin W, Brinckmann P, Leivseth G, Biggemann M, Frobin W, Brinckmann P, Leivseth G, Biggemann M, Reikeras O. Precision measurement of segmental motion from flexion-extension radiographs of the lumbar spine. Clin Biomech (Bristol, Avon). 1996;11(8):457–465.

19. Cook SD, Patron LP, Christakis PM, Bailey KJ, Banta C, Glazer PA. Comparison of methods for determining the presence and extent of anterior lumbar interbody fusion. Spine (Phila Pa 1976). 2004;29(10):1118–1123.

20. Tan GH, Goss BG, Thorpe PJ, Williams RP. CT-based classification of long spinal allograft fusion. Eur Spine J. 2007;16(11):1875–1881.

21. Choi JY, Sung KH. Subsidence after anterior lumbar interbody fusion using paired stand-alone rectangular cages. Eur Spine J. 2006;15(1):16–22.

22. Isaacs RE, Sembrano JN, Tohmeh AG, Group SDS. Two-year comparative outcomes of MIS lateral and MIS transforaminal interbody fusion in the treatment of degenerative spondylolisthesis: part II: radiographic findings. Spine (Phila Pa 1976). 2016;41(Suppl 8):S133–S144.

23. Mroz TE, Wang JC, Hashimoto R, Norvell DC. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976). 2010;35(Suppl S86–S104.

24. Pimenta L, Marchi L, Oliveira L, Coutinho E, Amaral R. A prospective, randomized, controlled trial comparing radiographic and clinical outcomes between stand-alone lateral interbody lumbar fusion with either silicate calcium phosphate or rh-BMP2. J Neurosurg. 2013;74(6):343–350.

25. Mulconrey DS, Bridwell KH, Flynn J, Cronen GA, Rose PS. Bone morphogenetic protein (RrhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum two-year evaluation of fusion. Spine (Phila Pa 1976). 2008;33(20):2153–2159.

26. Chrustel J, Low JB, Whang PG, Patel AA. Complications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine. Spine (Phila Pa 1976). 2013;38(16):E1020–E1027.

27. Mobbs RJ, Phan K, Mallham G, Seek K, Rao PJ. Lumbar interbody fusion: techniques, indications and comparison of interbody fusion options including PLIF, TLIF, MISTLIF, OLIF/ATP, LLIF and ALIF. J Spine Surg. 2015;1(1):2–18.

Disclosures and COI: The senior author (M.Y.W.) serves as a consultant for Depuy Spine, Aesculap Spine, JoiMax, and K2M; receives royalties from Children’s Hospital of Los Angeles, Depuy Spine, Springer Publishing, and Quality Medical Publishing; holds stocks in Innovative Surgical Devices and Spinicity; and has grants from the Department of Defense. There are no other potential conflicts of interest to report. The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. No funding was received for this research.

The device that is the subject of this manuscript is being evaluated as part of an ongoing FDA-approved investigational protocol (IDE) or corresponding national protocol for lumbar interbody fusion. This device is currently FDA-approved for human use in vertebroplasty.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required. This article does not contain any studies with animals performed by any of the authors.

Corresponding Author: John Paul G. Kolcun, Lois Pope Life Center, Department of Neuro-
logical Surgery, 1095 NW 14th Terrace, Miami, FL 33136. Phone: (305) 243-3294; Fax: (305) 243-3337; Email: jpk73@med.miami.edu.

Published 31 August 2019

This manuscript is generously published free of charge by ISASS, the International Society for the Advancement of Spine Surgery. Copyright © 2019 ISASS. To see more or order reprints or permissions, see http://ijssurgery.com.